Daniel Grima, M.Sc.
General Manager, Value and Evidence
Daniel is an expert in the development of global reimbursement strategies, and in health economic modeling and analysis. He has worked on hundreds of economic analyses across a range of activities including strategic market access planning, model development, local market analyses, indirect treatment comparison, and value communication. Daniel joined EVERSANA as part of the acquisition of the Cornerstone Research Group, which he co-founded and grew into a global leader in Health Economic Research. Prior to that, Daniel was Director at Aventis Pharmaceuticals where he was responsible for the development of global health economic research and market access strategies for the several portfolios. This role provided important insights into the need for simplified communication of health economics and the opportunity to leverage health economic research to support product marketing and sales. Before Aventis, Daniel was the Director of Health Economics and Outcomes Research for Innovus Research (now Optum Life Sciences), where he developed studies for the Canadian, American, European, Latin American, and Asian markets.
Since 1994, Daniel worked and published in a wide range of therapeutic areas, including immunology, sexually transmitted diseases, infectious diseases, ophthalmology, vaccination, oncology, respiratory medicine, rheumatology, and neurology. Daniel’s academic training includes a B.Sc. in Toxicology and an M.Sc. with a specialization in Clinical Biochemistry, both from the University of Toronto